EUVIMEDEUVIMED entdecken
Crossref

Elevated baseline CTX levels predict enhanced therapeutic efficacy of zoledronic acid in augmenting lumbar spine bone mineral density among Chinese osteoporosis patients

Qing Zhang, Wenxue Gao, Xiaojuan Xu, Ran Cui, Bin Su

Osteoporosis International · 2025

DOI: 10.1007/s00198-025-07448-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Osteoporosis International, 2025. Verfasst von Qing Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Transfusion, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, 301 Middle Yanchang Road, Shanghai, 200072, China. Hauptthemen laut MEDLINE: Zoledronic Acid, Bone Density, Bone Density Conservation Agents, Osteoporosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Science and Technology Commission of Shanghai Municipality, Research-oriented Physician of Shanghai Tenth People's Hospital, Clinical research project of Shanghai Tenth People's Hospital of Tongji University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study examined the link between baseline CTX levels and zoledronic acid's effectiveness in boosting bone density in osteoporosis patients. Among 472 Chinese patients, higher initial CTX levels correlated with greater lumbar spine bone density improvement after treatment. However, no such correlation was found for hip or femoral neck bones. This suggests CTX levels may aid in treatment selection for lumbar spine, though further research is needed. The findings have clinical implications for optimizing osteoporosis treatment. PURPOSE: To elucidate the correlation between baseline CTX levels and the therapeutic efficacy of zoledronic acid in augmenting bone mineral density (BMD) among individuals with osteoporosis. METHODS: This study studied patients diagnosed with primary osteoporosis who were hospitalized at least twice and received annual zoledronic acid therapy. Patients were stratified into three groups based on their initial CTX levels prior to zoledronic acid administration. ANOVA was employed to compare BMD alterations across the groups. Generalized estimating equations (GEE) were utilized to analyze the relationship between baseline CTX levels and subsequent BMD changes post-zoledronic acid treatment. Statistical analyses were conducted using SPSS version 26.0. RESULTS: A total of 472 patients were evaluated and categorized into three cohorts according to their initial CTX levels, arranged in ascending order. Notably, group 3, characterized by the highest initial CTX levels, demonstrated a significantly more pronounced increase in lumbar spine BMD compared to the other two groups. Specifically, when group 1 served as the reference, group 3 exhibited a 0.4-unit elevation in lumbar spine T-score. Conversely, no discernible relationship was observed between baseline CTX levels and BMD changes in the hip or femoral neck following zoledronic acid treatment. CONCLUSIONS: Our findings among a Chinese population indicate that elevated CTX levels, particularly exceeding 0.480 ng/ml, are notably associated with enhanced therapeutic efficacy of zoledronic acid in boosting lumbar spine BMD. However, this correlation appears less robust with respect to improvements in hip and femoral neck BMD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Zoledronic AcidBone DensityBone Density Conservation AgentsOsteoporosisCollagen Type IPeptidesHumansLumbar VertebraeFemaleMaleMiddle AgedAgedBiomarkersFemur NeckTreatment OutcomeAbsorptiometry, PhotonAged, 80 and overEast Asian People

Stichwörter der Autor:innen

BisphosphonateBone mineral densityFractureOsteoporosisZoledronic acid

Substanzen

Zoledronic AcidBone Density Conservation AgentsBiomarkerscollagen type I trimeric cross-linked peptideCollagen Type IPeptides

Autor:innen und Institutionen

  • Department of Transfusion, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, 301 Middle Yanchang Road, Shanghai, 200072, China.
  • Clinical Research Unit, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200072, China.
  • Kangqiao Community Health Service Center, Pudong New Area, Shanghai, 201906, China.
  • Department of Endocrinology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, 301 Middle Yanchang Road, Shanghai, 200072, China. cuiran1172@163.com.
  • Department of Transfusion, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, 301 Middle Yanchang Road, Shanghai, 200072, China. 1400801@tongji.edu.cn.

Förderung

  • Science and Technology Commission of Shanghai Municipality
  • Research-oriented Physician of Shanghai Tenth People's Hospital
  • Clinical research project of Shanghai Tenth People's Hospital of Tongji University
  • Teaching research project of Shanghai Tenth People's Hospital of Tongji University
  • the National Natural Science Foundation hospital cultivation project of Shanghai Tenth People's Hospital of Tongji University
  • Science and Technology Commission of Shanghai Chongming District
  • Shanghai Hospital Development Center Foundation
  • Research-oriented Physician of Shanghai Tenth People’s Hospital

Zitieren

APA

Zhang, Q., Gao, W., Xu, X., Cui, R., & Su, B. (2025). Elevated baseline CTX levels predict enhanced therapeutic efficacy of zoledronic acid in augmenting lumbar spine bone mineral density among Chinese osteoporosis patients. Osteoporosis International. https://doi.org/10.1007/s00198-025-07448-7

Vancouver

Zhang Q, Gao W, Xu X, Cui R, Su B. Elevated baseline CTX levels predict enhanced therapeutic efficacy of zoledronic acid in augmenting lumbar spine bone mineral density among Chinese osteoporosis patients. Osteoporosis International. 2025. doi:10.1007/s00198-025-07448-7

BibTeX
@article{Zhang2025,
  author = {Zhang, Qing and Gao, Wenxue and Xu, Xiaojuan and Cui, Ran and Su, Bin},
  title = {Elevated baseline CTX levels predict enhanced therapeutic efficacy of zoledronic acid in augmenting lumbar spine bone mineral density among Chinese osteoporosis patients},
  journal = {Osteoporosis International},
  year = {2025},
  doi = {10.1007/s00198-025-07448-7}
}
Kostenlos starten →